Table 2.
Immunosuppression and transplant outcomes
| Group I (n = 32) |
Group II (n = 36) |
P-value | |
|---|---|---|---|
| Pre-transplant desensitization* | 3 (9.4%) | 4 (11.1%) | 1.000 |
| Induction therapy | 1.000 | ||
| r-ATG | 23 (71.9%) | 25 (69.4%) | |
| Basiliximab | 9 (28.1%) | 11 (30.6%) | |
| ESW | 25 (78.1%) | 22 (61.1%) | 0.189 |
| mToR conversion prior to BKPyV viremia diagnosis | 2 (6.3%) | 5 (13.9%) | 0.434 |
| BPAR | 4 (12.5%) | 8 (22.2%) | 0.353 |
| Steroid-resistant cellular rejection | 1 (25%) | 0 (0%) | 0.333 |
| AMR | 2 (6.3%) | 5 (13.9%) | 0.434 |
| Time (days) to BKPyV viremia diagnosis after transplant | 119.3 ± 83.0 | 143.1 ± 80.1 | 0.234 |
| Graft loss | 6 (18.8%) | 5 (13.9%) | 0.744 |
| Patient death | 3 (9.4%) | 3 (8.3%) | 1.000 |
| Follow-up (days) | 1428.0 ± 727.4 | 1411.0 ± 680.7 | 0.921 |
*
Desensitization: patients with anti-donor antibodies receive a regimen of plasma exchange and intravenous immunoglobulin (IVIG) prior to transplantation.
r-ATG, rabbit anti-thymocyte globulin; ESW, early steroid withdrawal; mToR, mammalian target of rapamycin inhibitor (i.e., sirolimus, everolimus); BKPyV, human BK polyomavirus; BPAR, biopsy-proven acute rejection; AMR, antibody-mediated rejection.